KPTI

SEC source: 0000950170-25-012326 · ownership.xml · nonDerivative · entry 1

Macomber Lori · CIK 0001968671 · EVP, CFO & Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 160,000

F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Inducement Stock Incentive Plan, as amended (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in three equal annual installments beginning January 31, 2026.

SEC source: 0000950170-25-002819 · ownership.xml · nonDerivative · entry 1

Paulson Richard A. · CIK 0001804460 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,124,257

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

SEC source: 0000950170-24-133689 · ownership.xml · nonDerivative · entry 1

Paulson Richard A. · CIK 0001804460 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,128,312

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

SEC source: 0000950170-24-122274 · ownership.xml · nonDerivative · entry 1

Paulson Richard A. · CIK 0001804460 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,131,932

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $0.9101 to $0.9350, inclusive. The reporting person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0000950170-24-113263 · ownership.xml · nonDerivative · entry 1

Paulson Richard A. · CIK 0001804460 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,135,607

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

SEC source: 0000950170-24-103998 · ownership.xml · nonDerivative · entry 1

Cheng Sohanya Roshan · CIK 0001865796 · EVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 404,051

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 7, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

F2 · balance_after: Includes 15,898 shares acquired under the Karyopharm Therapeutics Inc. Amended & Restated 2013 Employee Stock Purchase Plan on April 30, 2024.

SEC source: 0000950170-24-104038 · ownership.xml · nonDerivative · entry 1

Mano Michael · CIK 0001837741 · SVP, General Counsel&Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 273,881

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 16, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

SEC source: 0000950170-24-104033 · ownership.xml · nonDerivative · entry 1

Paulson Richard A. · CIK 0001804460 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,139,214

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

SEC source: 0000950170-24-104031 · ownership.xml · nonDerivative · entry 1

Mason Michael · CIK 0001514291 · EVP, CFO & Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 391,054

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

SEC source: 0000950170-24-094087 · ownership.xml · nonDerivative · entry 1

Paulson Richard A. · CIK 0001804460 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,142,881

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

SEC source: 0000950170-24-088589 · ownership.xml · nonDerivative · entry 1

Poulton Stuart · CIK 0001942597 · EVP, Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 326,628

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 18, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

SEC source: 0000950170-24-082417 · ownership.xml · nonDerivative · entry 1

Paulson Richard A. · CIK 0001804460 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,146,489

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

SEC source: 0000950170-24-070991 · ownership.xml · nonDerivative · entry 6

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 0

F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $0.9303 to $0.965, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

F5 · ownership.nature: The shares are held directly by Delphi BioInvestments VIII, L.P. ("DB VIII"). DMP VIII is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein.

SEC source: 0000950170-24-070991 · ownership.xml · nonDerivative · entry 5

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 0

F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $0.9303 to $0.965, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

F4 · ownership.nature: The shares are held directly by Delphi Ventures VIII, L.P. ("DV VIII"). Delphi Management Partners VIII, L.L.C. ("DMP VIII"), is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein.

SEC source: 0000950170-24-070991 · ownership.xml · nonDerivative · entry 4

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 2,240

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $0.97 to $1.0302, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

F5 · ownership.nature: The shares are held directly by Delphi BioInvestments VIII, L.P. ("DB VIII"). DMP VIII is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein.

SEC source: 0000950170-24-070991 · ownership.xml · nonDerivative · entry 3

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 229,308

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $0.97 to $1.0302, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

F4 · ownership.nature: The shares are held directly by Delphi Ventures VIII, L.P. ("DV VIII"). Delphi Management Partners VIII, L.L.C. ("DMP VIII"), is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein.

SEC source: 0000950170-24-070991 · ownership.xml · nonDerivative · entry 2

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 3,385

F1 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $0.899 to $0.989, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

F5 · ownership.nature: The shares are held directly by Delphi BioInvestments VIII, L.P. ("DB VIII"). DMP VIII is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein.

SEC source: 0000950170-24-070991 · ownership.xml · nonDerivative · entry 1

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 346,615

F1 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $0.899 to $0.989, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

F4 · ownership.nature: The shares are held directly by Delphi Ventures VIII, L.P. ("DV VIII"). Delphi Management Partners VIII, L.L.C. ("DMP VIII"), is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein.

SEC source: 0000950170-24-068969 · ownership.xml · nonDerivative · entry 6

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 7,911

F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $0.93 to $0.9985, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

F5 · ownership.nature: The shares are held directly by Delphi BioInvestments VIII, L.P. ("DB VIII"). DMP VIII is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein.

SEC source: 0000950170-24-068969 · ownership.xml · nonDerivative · entry 5

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 810,133

F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $0.93 to $0.9985, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

F4 · ownership.nature: The shares are held directly by Delphi Ventures VIII, L.P. ("DV VIII"). Delphi Management Partners VIII, L.L.C. ("DMP VIII"), is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein.

SEC source: 0000950170-24-069856 · ownership.xml · nonDerivative · entry 1

Paulson Richard A. · CIK 0001804460 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,150,105

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

SEC source: 0000950170-24-069860 · ownership.xml · nonDerivative · entry 1

Mason Michael · CIK 0001514291 · EVP, CFO & Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 398,104

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

SEC source: 0000950170-24-068969 · ownership.xml · nonDerivative · entry 4

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 11,209

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $0.9643 to $1.06, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

F5 · ownership.nature: The shares are held directly by Delphi BioInvestments VIII, L.P. ("DB VIII"). DMP VIII is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein.

SEC source: 0000950170-24-068969 · ownership.xml · nonDerivative · entry 3

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 1,147,875

F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $0.9643 to $1.06, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

F4 · ownership.nature: The shares are held directly by Delphi Ventures VIII, L.P. ("DV VIII"). Delphi Management Partners VIII, L.L.C. ("DMP VIII"), is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein.

SEC source: 0000950170-24-068969 · ownership.xml · nonDerivative · entry 2

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 14,697

F1 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $0.9308 to $0.9996, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

F5 · ownership.nature: The shares are held directly by Delphi BioInvestments VIII, L.P. ("DB VIII"). DMP VIII is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein.

SEC source: 0000950170-24-068969 · ownership.xml · nonDerivative · entry 1

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 1,505,131

F1 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $0.9308 to $0.9996, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

F4 · ownership.nature: The shares are held directly by Delphi Ventures VIII, L.P. ("DV VIII"). Delphi Management Partners VIII, L.L.C. ("DMP VIII"), is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein.

SEC source: 0000950170-24-066781 · ownership.xml · derivative · entry 1

Greene Barry E · CIK 0001291963 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 69,000

Underlying: Common Stock · 69,000 shares

Expires 2034-05-28

F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on May 29, 2025.

SEC source: 0000950170-24-066785 · ownership.xml · derivative · entry 1

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 69,000

Underlying: Common Stock · 69,000 shares

Expires 2034-05-28

F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on May 29, 2025.

SEC source: 0000950170-24-066771 · ownership.xml · derivative · entry 1

BOHLIN GAREN G · CIK 0001254705 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 69,000

Underlying: Common Stock · 69,000 shares

Expires 2034-05-28

F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on May 29, 2025.

SEC source: 0000950170-24-066786 · ownership.xml · derivative · entry 1

Schor Chen · CIK 0001340875 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 69,000

Underlying: Common Stock · 69,000 shares

Expires 2034-05-28

F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on May 29, 2025.

SEC source: 0000950170-24-066787 · ownership.xml · derivative · entry 1

Su Zhen · CIK 0001991642 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,587

Underlying: Common Stock · 50,587 shares

Expires 2034-05-28

F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on May 29, 2025.

SEC source: 0000950170-24-066784 · ownership.xml · derivative · entry 1

Oliger Christy J. · CIK 0001822092 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 69,000

Underlying: Common Stock · 69,000 shares

Expires 2034-05-28

F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on May 29, 2025.

SEC source: 0000950170-24-066782 · ownership.xml · derivative · entry 1

Mirza Mansoor Raza · CIK 0001588389 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 69,000

Underlying: Common Stock · 69,000 shares

Expires 2034-05-28

F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on May 29, 2025.

SEC source: 0000950170-24-054686 · ownership.xml · nonDerivative · entry 1

Paulson Richard A. · CIK 0001804460 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,153,697

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

SEC source: 0000950170-24-046871 · ownership.xml · nonDerivative · entry 1

Rangwala Reshma · CIK 0001825322 · EVP & Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 342,931

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on April 4, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

SEC source: 0000950170-24-042350 · ownership.xml · nonDerivative · entry 1

Paulson Richard A. · CIK 0001804460 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,157,273

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

SEC source: 0000950170-24-027153 · ownership.xml · nonDerivative · entry 1

Paulson Richard A. · CIK 0001804460 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,160,836

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $1.28 to $1.30, inclusive. The reporting person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0000950170-24-025189 · ownership.xml · nonDerivative · entry 2

Cheng Sohanya Roshan · CIK 0001865796 · EVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 393,509

F3 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 7, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of performance-based restricted stock units. The sale does not represent a discretionary trade by the reporting person.

SEC source: 0000950170-24-025190 · ownership.xml · nonDerivative · entry 2

Mano Michael · CIK 0001837741 · SVP, General Counsel&Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 277,852

F3 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 16, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of performance-based restricted stock units. The sale does not represent a discretionary trade by the reporting person.

SEC source: 0000950170-24-025188 · ownership.xml · nonDerivative · entry 2

Paulson Richard A. · CIK 0001804460 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,164,409

F3 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of performance-based restricted stock units. The sale does not represent a discretionary trade by the reporting person.

SEC source: 0000950170-24-025193 · ownership.xml · nonDerivative · entry 2

Rangwala Reshma · CIK 0001825322 · EVP & Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 349,720

F3 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on April 4, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of performance-based restricted stock units. The sale does not represent a discretionary trade by the reporting person.

SEC source: 0000950170-24-025192 · ownership.xml · nonDerivative · entry 2

Poulton Stuart · CIK 0001942597 · EVP, Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 329,511

F3 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 18, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of performance-based restricted stock units. The sale does not represent a discretionary trade by the reporting person.

SEC source: 0000950170-24-025191 · ownership.xml · nonDerivative · entry 2

Mason Michael · CIK 0001514291 · EVP, CFO & Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 398,756

F3 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of performance-based restricted stock units. The sale does not represent a discretionary trade by the reporting person.

SEC source: 0000950170-24-025189 · ownership.xml · nonDerivative · entry 1

Cheng Sohanya Roshan · CIK 0001865796 · EVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 398,618

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 7, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $1.11 to $1.18, inclusive. The reporting person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0000950170-24-025190 · ownership.xml · nonDerivative · entry 1

Mano Michael · CIK 0001837741 · SVP, General Counsel&Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 281,428

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 16, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $1.12 to $1.18, inclusive. The reporting person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0000950170-24-025188 · ownership.xml · nonDerivative · entry 1

Paulson Richard A. · CIK 0001804460 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,183,783

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $1.12 to $1.18, inclusive. The reporting person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0000950170-24-025193 · ownership.xml · nonDerivative · entry 1

Rangwala Reshma · CIK 0001825322 · EVP & Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 355,689

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on April 4, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $1.11 to $1.18, inclusive. The reporting person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0000950170-24-025192 · ownership.xml · nonDerivative · entry 1

Poulton Stuart · CIK 0001942597 · EVP, Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 335,666

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 18, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $1.12 to $1.18, inclusive. The reporting person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0000950170-24-025191 · ownership.xml · nonDerivative · entry 1

Mason Michael · CIK 0001514291 · EVP, CFO & Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 404,918

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $1.12 to $1.18, inclusive. The reporting person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0000950170-24-023285 · ownership.xml · nonDerivative · entry 1

Cheng Sohanya Roshan · CIK 0001865796 · EVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 420,458

F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in three equal annual installments beginning February 28, 2025.